INTREXON appoints Lupin CEO Vinita Gupta to its Board of Directors

INTREXON Corporation announced the appointment of Lupin’s CEO Vinita Gupta to its Board of Directors effective from April 25, 2017.

Ms. Gupta has served as CEO of India-based Lupin since 2012.  During her tenure as CEO, Lupin’s revenue and global footprint has expanded significantly. Notably, the acquisition of U.S-based drugmaker Gavis in 2016 provided the Company a manufacturing center in the U.S. and complemented their R&D capabilities in complex generics and controlled substances.  Ms. Gupta has served as a director of Lupin since 2001 and serves on its Risk Management Committee.  In addition, she has served as the CEO and Chairperson of Lupin Pharmaceuticals, Inc., the U.S. wholly owned subsidiary of Lupin, since 2003 and as a Director on the Board of Lupin’s Japanese subsidiary Kyowa Pharmaceuticals, since 2007.

INTREXON Chairman and CEO, Randal J. Kirk said that Vinita’s exemplary leadership and management experience has been instrumental in formulating and executing strategy to help Lupin emerge as a leading global pharmaceutical corporation. On behalf of their Board of Directors, He welcome Vinita as her significant knowledge of all aspects of business from operations to government relations and finance to mergers and acquisitions will be a great asset for Intrexon.